Panbela Therapeutics (PBLA) Competitors $0.01 +0.00 (+0.91%) As of 10/3/2025 01:05 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. PTPI, BPTSY, HEPA, BPTH, ORGS, BON, VINC, NCNA, VRPX, and SMFLShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Petros Pharmaceuticals (PTPI), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Bio-Path (BPTH), Orgenesis (ORGS), Bon Natural Life (BON), Vincerx Pharma (VINC), NuCana (NCNA), Virpax Pharmaceuticals (VRPX), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Petros Pharmaceuticals Biophytis Hepion Pharmaceuticals Bio-Path Orgenesis Bon Natural Life Vincerx Pharma NuCana Virpax Pharmaceuticals Smart for Life Panbela Therapeutics (NASDAQ:PBLA) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Is PBLA or PTPI more profitable? Panbela Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Petros Pharmaceuticals N/A -78.22%-23.50% Do institutionals & insiders hold more shares of PBLA or PTPI? 4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, PBLA or PTPI? Panbela Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Which has stronger earnings & valuation, PBLA or PTPI? Petros Pharmaceuticals has higher revenue and earnings than Panbela Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00Petros Pharmaceuticals$5.11M0.15-$8.16M-$52.910.00 Does the media prefer PBLA or PTPI? In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Panbela Therapeutics Neutral Petros Pharmaceuticals Neutral SummaryPetros Pharmaceuticals beats Panbela Therapeutics on 7 of the 9 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54K$1.01B$6.08B$10.55BDividend YieldN/A4.84%5.68%4.70%P/E Ratio0.001.2578.0526.71Price / SalesN/A25.34577.94179.90Price / CashN/A17.6537.7961.25Price / Book0.006.9612.556.56Net Income-$25.26M-$5.93M$3.31B$277.70M7 Day PerformanceN/A2.07%4.28%2.41%1 Month PerformanceN/A4.52%7.85%9.30%1 Year PerformanceN/A42.08%71.37%31.22% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.115 of 5 stars$0.01+0.9%N/A-96.9%$54KN/A0.006PTPIPetros Pharmaceuticals0.3249 of 5 stars$0.02-5.9%N/A-99.7%$748K$5.11M-0.0120Gap DownBPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030HEPAHepion Pharmaceuticals0.1399 of 5 stars$0.05-1.2%N/A-99.8%$572KN/A-0.0120Gap UpBPTHBio-Path1.6464 of 5 stars$0.06-19.6%N/A-93.1%$532KN/A0.0010Short Interest ↓Gap UpORGSOrgenesisN/A$0.11-89.0%N/A-98.8%$528K$662K0.00150Gap DownBONBon Natural Life0.5502 of 5 stars$1.95flatN/AN/A$330K$23.84M0.00100Short Interest ↑VINCVincerx Pharma2.5696 of 5 stars$0.04+4.3%$40.00+90,809.1%-99.6%$230KN/A0.0060Short Interest ↑Gap UpNCNANuCana0.6017 of 5 stars$4.64+21.1%N/A-98.8%$120KN/A-0.0130Positive NewsHigh Trading VolumeVRPXVirpax Pharmaceuticals0.0585 of 5 stars$0.04+39.8%N/A-99.9%$44KN/A0.007Gap DownSMFLSmart for LifeN/A$0.01-16.7%N/A-85.0%$35K$11.11M0.00110Gap Down Related Companies and Tools Related Companies Petros Pharmaceuticals Competitors Biophytis Competitors Hepion Pharmaceuticals Competitors Bio-Path Competitors Orgenesis Competitors Bon Natural Life Competitors Vincerx Pharma Competitors NuCana Competitors Virpax Pharmaceuticals Competitors Smart for Life Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
